GLP-1 Support Stack Companion support for clients on Ozempic, Wegovy, Mounjaro, or Zepbound
Short-acting GLP-1 analogs (Table 2) reduce glucose response after eating food by increasing insulin secretion and delaying gastric emptying
8 This study, which took place over a five-year period, surely contributed to the FDAs approval of semaglutide in early 2024 for use in this population, and demonstrated that, in addition to managing diabetes and obesity, GLP1 receptor agonists offer value in reducing cardiovascular event risk
If the levels get too high, the doctor must lower the dose
Appetite ReshapingVisceral Fat ReductionWeight Loss Price range: $230.00 through $385.00 Only the lyophilized product is provided
Ozempic (semaglutide) is a prescription GLP-1 receptor agonist originally approved for type 2 diabetes management